Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease

Background and aims Cystic Fibrosis (CF) lung disease is characterized by progressively declining lung function and represents a major factor contributing to the high morbidity and mortality associated with CF. However, apart from spirometry, respiratory disease surrogate markers reliably indicating CF lung disease and the occurrence of pulmonary exacerbations (PEx) are still lacking. Within this study, we aimed to identify new experimental biomarkers for the detection of CF lung disease. Methods 54 adult and 26 pediatric CF patients were included in the study and serum concentrations of MMP-1, -2, -8, -9, -13, TIMP-1, TIMP-2, YKL-40, hyaluronic acid, procollagen III peptide were quantified by ELISA. CF lung disease was diagnosed by lung function test, PEx was defined based on a clinical scoring established by Rosenfeld in 2001. Results Adults and children with moderate to severe CF lung disease exhibited significantly increased serum expression of MMP-8, MMP-9, YKL-40 and TIMP-1. Further, MMP-8, MMP-9 and YKL-40 were significantly increased in adult CF patients suffering from PEx compared to those without clinical signs of respiratory exacerbation. MMP-8, MMP-9, YKL-40, and TIMP-1 serum levels were unaffected by the presence or absence of CF liver disease or pancreatic insufficiency. Conclusions MMP-8, MMP-9, and YKL-40 might serve as novel non-invasive biomarkers of CF lung disease and PEx.

[1]  P. Sly,et al.  Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease , 2014, BMC Pulmonary Medicine.

[2]  Michael E. Hall,et al.  Using plasma matrix metalloproteinase-9 and monocyte chemoattractant protein-1 to predict future cardiovascular events in subjects with carotid atherosclerosis. , 2014, Atherosclerosis.

[3]  C. Liapis,et al.  The Impact of Type 2 Diabetes and Atorvastatin Treatment on Serum Levels of MMP-7 and MMP-8 , 2014, Experimental and Clinical Endocrinology & Diabetes (Barth).

[4]  D. Sin,et al.  Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. , 2013, Chest.

[5]  J. Hilden,et al.  Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. , 2013, Immunobiology.

[6]  E. Roeb,et al.  Serum Proteome Profiling Identifies Novel and Powerful Markers of Cystic Fibrosis Liver Disease , 2013, PloS one.

[7]  S. Sagel,et al.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. , 2012, American journal of respiratory and critical care medicine.

[8]  Bo Hyun Kim,et al.  Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. , 2012, Journal of diabetes and its complications.

[9]  O. Eickelberg,et al.  The Chitinase-Like Protein YKL-40 Modulates Cystic Fibrosis Lung Disease , 2011, PloS one.

[10]  J. McBride,et al.  Approach to treating cystic fibrosis pulmonary exacerbations varies widely across us CF care centers , 2011, Pediatric pulmonology.

[11]  B. Strandvik,et al.  Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  A. Lewiński,et al.  Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia , 2011, Archives of medical science : AMS.

[13]  A. Gaggar,et al.  The role of matrix metalloproteinases in cystic fibrosis lung disease , 2011, European Respiratory Journal.

[14]  J. Clancy,et al.  Human Neutrophil Elastase-Mediated Cleavage Sites of MMP-9 and TIMP-1: Implications to Cystic Fibrosis Proteolytic Dysfunction , 2010, Molecular medicine.

[15]  P. Kiener,et al.  YKL-40 Is Elevated in Patients with Chronic Obstructive Pulmonary Disease and Activates Alveolar Macrophages1 , 2008, The Journal of Immunology.

[16]  P. Davis,et al.  Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[17]  J. Clancy,et al.  A Novel Proteolytic Cascade Generates an Extracellular Matrix-Derived Chemoattractant in Chronic Neutrophilic Inflammation12 , 2008, The Journal of Immunology.

[18]  C. Rudolph,et al.  Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease , 2007, Nature Medicine.

[19]  J. Dziura,et al.  A chitinase-like protein in the lung and circulation of patients with severe asthma. , 2007, The New England journal of medicine.

[20]  Karen A Robinson,et al.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.

[21]  M. Boyle.  Adult cystic fibrosis. , 2007, JAMA.

[22]  J. Clancy,et al.  Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[23]  A. Gressner,et al.  Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[24]  A. Nicholson,et al.  Airway remodelling in children with cystic fibrosis , 2007, Thorax.

[25]  R. Kronmal,et al.  Association between pulmonary function and sputum biomarkers in cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[26]  Andrew J. Ewald,et al.  Matrix metalloproteinases and the regulation of tissue remodelling , 2007, Nature Reviews Molecular Cell Biology.

[27]  J. Foidart,et al.  Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. , 2006, European journal of pharmacology.

[28]  J. Friedland,et al.  Matrix metalloproteinases in destructive pulmonary pathology , 2005, Thorax.

[29]  M. Rosenfeld,et al.  Cystic fibrosis pulmonary exacerbations. , 2006, The Journal of pediatrics.

[30]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[31]  S. Sagel,et al.  Induced sputum matrix metalloproteinase‐9 correlates with lung function and airway inflammation in children with cystic fibrosis , 2005, Pediatric pulmonology.

[32]  E. Kerem,et al.  Standards of care for patients with cystic fibrosis: a European consensus. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[33]  Richard C Boucher,et al.  Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice , 2004, Nature Medicine.

[34]  P. Marteau,et al.  Discussion on genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. , 2003, Gastroenterology.

[35]  M. Corey,et al.  Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. , 2002, Gastroenterology.

[36]  F. Ratjen,et al.  Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha , 2002, Thorax.

[37]  Rachel Gault.  Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. , 2002, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

[38]  N. McElvaney,et al.  Interleukin-8 Up-regulation by Neutrophil Elastase Is Mediated by MyD88/IRAK/TRAF-6 in Human Bronchial Epithelium* , 2001, The Journal of Biological Chemistry.

[39]  J. Emerson,et al.  Defining a pulmonary exacerbation in cystic fibrosis. , 2001, The Journal of pediatrics.

[40]  A. Turman,et al.  Respiratory-related neuronal activity in the nucleus ambiguus-retroambigualis complex and their responses to peripheral and central stimulation in the rat , 2001, Respiratory Research.

[41]  R. Henry,et al.  Defining an exacerbation of pulmonary disease in cystic fibrosis * , 2001, Pediatric pulmonology.

[42]  S. Shapiro,et al.  Matrix metalloproteinases in lung biology , 2000, Respiratory research.

[43]  P. Junker,et al.  YKL-40, a matrix protein of specific granules in neutrophils, is elevated in serum of patients with community-acquired pneumonia requiring hospitalization. , 1999, The Journal of infectious diseases.

[44]  H. Nielsen,et al.  YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. , 1998, Proceedings of the Association of American Physicians.

[45]  M. Corey,et al.  Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. , 1997, The Journal of pediatrics.

[46]  M. Corey,et al.  Determinants of mortality from cystic fibrosis in Canada, 1970-1989. , 1996, American journal of epidemiology.

[47]  G. Döring.  The role of neutrophil elastase in chronic inflammation. , 1994, American journal of respiratory and critical care medicine.

[48]  T. Boat,et al.  Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. , 1994, The Journal of pediatrics.

[49]  D. Williams,et al.  Human neutrophil chemokinesis and polarization induced by hyaluronic acid derivatives. , 1993, Biomaterials.

[50]  M. Corey,et al.  Prediction of mortality in patients with cystic fibrosis. , 1992, The New England journal of medicine.